Skip to main content

Advertisement

SpringerLink
Log in

A Comprehensive Evaluation of Prognostic Value and Immune Infiltration of KDM1 Family in Hepatocellular Carcinoma

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in the world. Previous studies indicated that the expression of the KDM1 genes (KDM1s), members of the amine oxidase superfamily, has prognostic value for breast and prostate cancer and malignant neuroblastoma. This study aimed to investigate the expression of KDM1s, their prognostic value, and their correlation with immune infiltration in patients with HCC.

Methods

Multiomics analyses were utilized to analyze differential expression, prognostic value, genetic alteration, and immune cell infiltration of KDM1s in patients with HCC.

Results

The high expression of KDM1A indicated poor overall survival (OS) and disease-free survival, whereas the high expression of KDM1B was significantly associated with poor OS. The genetic alterations and biological interaction network of KDM1s may provide detailed information for the dysregulated function of KDM1s in patients with HCC. KDM1-related signaling pathways and miRNA targets were explored and may provide value as therapeutic targets or tumor progression markers. The increased mRNA expression of KDM1s was significantly correlated with the infiltration of diverse immune cells in HCC.

Conclusions

This data-driven study indicates that KDM1s are promising prognostic biomarkers for survival and have the potential to become novel molecular targets in HCC treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  2. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147(2):317–30.

    Article  CAS  Google Scholar 

  3. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–91.

    Article  Google Scholar 

  4. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):361–79.

    Article  Google Scholar 

  5. Selcuk H. Prognostic factors and staging systems in hepatocellular carcinoma. Exp Clin Transplant. 2017;15(Suppl 2):45–9.

    PubMed  Google Scholar 

  6. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.

    Article  Google Scholar 

  7. Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205(1):108–23.

    Article  Google Scholar 

  8. Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156(2):510–24.

    Article  Google Scholar 

  9. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.

    Article  CAS  Google Scholar 

  10. Arifuzzaman S, Khatun MR, Khatun R. Emerging of lysine demethylases (KDMs): from pathophysiological insights to novel therapeutic opportunities. Biomed Pharmacother. 2020;129: 110392.

    Article  CAS  Google Scholar 

  11. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol. 2007;8(4):307–18.

    Article  CAS  Google Scholar 

  12. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811–6.

    Article  CAS  Google Scholar 

  13. Johansson C, Tumber A, Che K, et al. The roles of Jumonji-type oxygenases in human disease. Epigenomics. 2014;6(1):89–120.

    Article  CAS  Google Scholar 

  14. Maes T, Mascaro C, Ortega A, et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics. 2015;7(4):609–26.

    Article  CAS  Google Scholar 

  15. Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010;31(3):512–20.

    Article  CAS  Google Scholar 

  16. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436–9.

    Article  CAS  Google Scholar 

  17. Sakane C, Okitsu T, Wada A, Sagami H, Shidoji Y. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. Biochem Biophys Res Commun. 2014;444(1):24–9.

    Article  CAS  Google Scholar 

  18. Wang D, Han S, Peng R, et al. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. J Exp Clin Cancer Res. 2016;35:37.

    Article  CAS  Google Scholar 

  19. Yamada D, Kobayashi S, Yamamoto H, et al. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol. 2012;19(Suppl 3):S355–64.

    Article  Google Scholar 

  20. Yu S, Wang Y, Hou J, et al. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. PLoS ONE. 2020;15(4): e0231003.

    Article  CAS  Google Scholar 

  21. Zhang SC, Hu ZQ, Long JH, et al. Clinical implications of tumor-infiltrating immune cells in breast cancer. J Cancer. 2019;10(24):6175–84.

    Article  CAS  Google Scholar 

  22. Zuo S, Wei M, Wang S, Dong J, Wei J. Pan-cancer analysis of immune cell infiltration identifies a prognostic immune-cell characteristic score (ICCS) in lung adenocarcinoma. Front Immunol. 2020;11:1218.

    Article  CAS  Google Scholar 

  23. Sakamoto A, Hino S, Nagaoka K, et al. Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells. Cancer Res. 2015;75(7):1445–56.

    Article  CAS  Google Scholar 

  24. Kim S, Bolatkan A, Kaneko S, et al. Deregulation of the histone lysine-specific demethylase 1 is involved in human hepatocellular carcinoma. Biomolecules. 2019;9:12.

    Article  Google Scholar 

  25. Maksour S, Ooi L, Dottori M. More than a corepressor: the role of CoREST proteins in neurodevelopment. eNeuro. 2020;7:2.

    Article  Google Scholar 

  26. Hesham HM, Lasheen DS, Abouzid KAM. Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev. 2018;38(6):2058–109.

    Article  Google Scholar 

  27. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19(6):857–64.

    Article  CAS  Google Scholar 

  28. Klajn A, Ferrai C, Stucchi L, et al. The rest repression of the neurosecretory phenotype is negatively modulated by BHC80, a protein of the BRAF/HDAC complex. J Neurosci. 2009;29(19):6296–307.

    Article  CAS  Google Scholar 

  29. Lee M, Venkitaraman AR. A cancer-associated mutation inactivates a region of the high-mobility group protein HMG20b essential for cytokinesis. Cell Cycle. 2014;13(16):2554–63.

    Article  CAS  Google Scholar 

  30. Sica V, Bravo-San Pedro JM, Stoll G, Kroemer G. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int J Cancer. 2020;146(1):10–7.

    Article  CAS  Google Scholar 

  31. Berasain C, Elizalde M, Urtasun R, et al. Alterations in the expression and activity of pre-mRNA splicing factors in hepatocarcinogenesis. Hepat Oncol. 2014;1(2):241–52.

    Article  Google Scholar 

  32. Li T, Fu J, Zeng Z, et al. TIMER20 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14.

    Article  CAS  Google Scholar 

  33. Zhou R, Zhang J, Zeng D, et al. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer. Cancer Immunol Immunother. 2019;68(3):433–42.

    Article  CAS  Google Scholar 

  34. Jiang Q, Sun J, Chen H, et al. Establishment of an immune cell infiltration score to help predict the prognosis and chemotherapy responsiveness of gastric cancer patients. Front Oncol. 2021;11: 650673.

    Article  Google Scholar 

  35. Wang Y, Dong J, Quan Q, et al. Immune cell infiltration of the primary tumor microenvironment predicted the treatment outcome of chemotherapy with or without bevacizumab in metastatic colorectal cancer patients. Front Oncol. 2020;10:581051.

    Article  Google Scholar 

  36. Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment. Gene Expr. 2020;20(1):53–65.

    Article  CAS  Google Scholar 

  37. Raybould AL, Sanoff H. Combination antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2020;7:133–42.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding

This study, including the journal’s Rapid Service Fee, was supported by Ministry of Science and Technology (Grant No. MOST 109 2314 B 016 009

Author Contributions

All authors meet the International Committee of Medical Journal Editors (ICMJE)criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Kuo Feng Hsu and Yen Ju Chen made contribution to the concept and design of this study. Kuo Feng Hsu, Shu-Hsien Wu and Yu Chun Ko collected and analyzed the data from several databases. Yu Chun Ko and Kuo Feng Hsu wrote the manuscript with input from Gang-Hua Lin, Chien H ua Lin, and Guo Shiou Liao.

Disclosures

Yu Chun Ko, Shu Hsien Wu, Gang Hua Lin, Chien Hua Lin, Guo Shiou Liao, Yen Ju Chen and Kuo Feng Hsu confirm that they have nothing to disclose.

Compliance with Ethics Guidelines

The data in this study is obtained from the public data sets, and therefore no ethical approval was required.

Data Availability

The data and materials used in this study are available from the corresponding author if reasonably required.

Author information

Authors and Affiliations

  1. Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan

    Yu-Chun Ko, Shu-Hsien Wu, Gang-Hua Lin, Chien-Hua Lin, Guo-Shiou Liao & Kuo-Feng Hsu

  2. Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan

    Shu-Hsien Wu

  3. IRCAD Taiwan, Department of Surgery, Chang-Bing Show Chwan Memorial Hospital, Taipei, Taiwan

    Chien-Hua Lin

  4. Epidemic Prevention and One Health Research Center, National Yang-Ming Chiao-Tung University, Taipei, Taiwan

    Yen-Ju Chen

Authors
  1. Yu-Chun Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-Hsien Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gang-Hua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chien-Hua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo-Shiou Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yen-Ju Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kuo-Feng Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yen-Ju Chen or Kuo-Feng Hsu.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 31051 kb)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ko, YC., Wu, SH., Lin, GH. et al. A Comprehensive Evaluation of Prognostic Value and Immune Infiltration of KDM1 Family in Hepatocellular Carcinoma. Adv Ther 39, 4568–4582 (2022). https://doi.org/10.1007/s12325-022-02275-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-022-02275-2

Keywords

Search

Navigation